

**Bettapharma, an Investment Project of
China Everbright Limited,
Listed on the ChiNext Board of Shenzhen Stock Exchange**

8 November 2016 - Betta Pharmaceuticals Co., Ltd. ("Bettapharma"), an investment project of **China Everbright Limited** ("CEL", stock code: 165.HK)'s Medical & Healthcare Fund, was listed on the ChiNext Board of Shenzhen Stock Exchange as the first listed innovative pharma company, with stock code: 300558.

Bettapharma is a national-level high-tech pharmaceutical company founded by a team of PhD returnees. Bettapharma has established an integrated organization of research and development, manufacturing, sales and marketing with emphasis R&D of innovative drugs and proprietary intellectual property rights. Ever since its establishment in 2003, it has fully committed to R&D and manufacturing of first class national innovative drugs with proprietary intellectual property rights directed at diseases with significant impacts on human health such as malignant tumors, diabetes, cardiovascular and cerebrovascular diseases and so forth. A first class national innovative drug called Icotinib Hydrochloride Tablets (Conmana) fully developed by Bettapharma is the first innovative small molecule-targeted anti-cancer drug with independent intellectual property rights in China.

Currently, CEL's Medical & Healthcare Fund has invested in 12 leading companies in healthcare industry at home and abroad, including Hanxiputai, Amcare, Xiuzheng Pharmaceutical, Ambrx and etc. and has successfully exited from Yuwell with profitable return.

For more information of Bettapharma, please visit: <http://en.bettapharma.com/>

-End-



About China Everbright Limited

China Everbright Limited (“CEL”, stock code: 165.HK), established in Hong Kong in 1997, persistently pursues its “Macro Asset Management” strategy with specific focuses on cross-border asset management and investment businesses. CEL manages a portfolio of private equity funds, venture capital funds, sector focus funds, mezzanine funds, hedge funds and principal investment funds, all operated via an international management platform, and provides overseas investors with opportunities to explore and invest in companies with fast growth potential in mainland China. CEL also seeks investment opportunities from overseas and provides diversified financial services for its clients on the mainland. As of 30 June 2016, CEL’s total fundraising scale reached over HK\$67.8 billion, with a total of 33 funds.

China Everbright Limited, a member of China Everbright Group, is the second-largest shareholder of Everbright Securities (stock code: 601788.SH, 6178.HK), a strategic shareholder of China Everbright Bank (stock code: 601818.SH, 6818.HK), the single largest shareholder of the Hong Kong-listed China Aircraft Leasing Group Holdings Limited (stock code: 1848.HK), the largest shareholder of Shanghai Jiabao Industry & Commerce (Group) Co., Ltd (stock code: 600622.SH) and the second-largest shareholder of the Singapore-listed Ying Li International Real Estate Limited (stock code : 5DM. SGX).

After the launch of "Shanghai-Hong Kong Stock Connect" on 10 April 2014, CEL became one of the first batch of specific stocks listed on The Stock Exchange of Hong Kong that can be directly traded by Mainland investors.

By practising its philosophy of “Making Wealth Simple”, CEL leverages its own substantial financial strength as well as the position and influence of China Everbright Group and its affiliated companies in the financial industry in China. As a result, the Group has successfully built huge cross-border social and business networks in Hong Kong and the Mainland, and established a reputable image in the market.

For more information about CEL, please visit www.everbright165.com.